Nov 18- StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells' research centers around the treatment for spinal cord injuries, visual problems that begin at the retina and...» Read More
Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.
Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...
David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.
One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.
The ETF that tracks biotechs, BBH, is up nearly 16 percent to date. Dominic Chu looks at whether there's still more room to run.
CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.
The Nasdaq biotech ETF IBB is coming back after tumbling more than 4 percent toward the end of last week. Is now the time to buy, with Eric Schmidt, Cowen & Co., and John Sonnier, with William Blair & Co.
A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.
Insight on malaria prevention, with Monceff Slaoui, GlaxoSmithKline, who is committed to the social responsibility of saving lives.
Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.
CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."
In terms of deal value, healthcare has logged the most M&A activity this year, according to Dealogic, after taking the top spot in both 2014 and 2013. CNBC's Morgan Brennan reports.
Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.
Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.
Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.
David Seaburg of Cowen has a way to trade pharma stocks into the ASCO meeting. He breaks it down, with Stacey Gilbert of Susquehanna and Brian Sullivan.
Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.
Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.
The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.
Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.